Praxis precision medicines, inc. announces proposed public offering

Boston, june 15, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock. all shares in the offering will be offered by praxis. in addition, praxis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering at the public offering price, less the underwriting discount and commission.
PRAX Ratings Summary
PRAX Quant Ranking